Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE WORLD BUSINESS NEWS IN BRIEF
February 26, 2001
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 26, 2001
-
ARCHIVE New Law Specific for Medical Devices Is Necessary: JFITMA President
February 26, 2001
-
ARCHIVE Kirin to Sponsor Genomic Medical Engineering Course at Tottori Univ.
February 26, 2001
-
ARCHIVE New ARIA Guidelines Prepared by WHO for Allergic Rhinitis
February 26, 2001
-
ARCHIVE Big Internet Influence on Pharma Fields Predicted: Mr Tanimura of So-net M3
February 26, 2001
-
ARCHIVE Strategies of AdvaMed, EUCOMED for Japan Revealed
February 26, 2001
-
ARCHIVE Suzuken to Quit Nursing Home Business
February 26, 2001
-
ARCHIVE OTC NEWS IN BRIEF
February 26, 2001
-
ARCHIVE Price of Seroquel Is 4 Times Higher Than Lullan
February 19, 2001
-
ARCHIVE RA Patient Group Holds Survey on Clinical Trials
February 19, 2001
-
ARCHIVE Long, Short-term Goals Must Be Set for Reform: JMA President
February 19, 2001
-
ARCHIVE Asthma Telemedicine Should Reduce Asthma Deaths: Teijin Seminar
February 19, 2001
-
ARCHIVE Chugai's '75-year History' Published
February 19, 2001
-
ARCHIVE Standard Drug Name, Lab Test Masters Completed
February 19, 2001
-
ARCHIVE RESEARCH AND DEVELOPMENT NEWS IN BRIEF
February 19, 2001
-
ARCHIVE Locate in Scotland, Scottish Trade International Move to New Office
February 19, 2001
-
ARCHIVE Average Bungyo Rate for All Programs Exceeds 40% for First Time
February 19, 2001
-
ARCHIVE Korosho Denies Need for Further Deregulation
February 19, 2001
-
ARCHIVE Sumitomo Revises Sales for 2002 Upward to \150 Billion: President Yokotsuka
February 19, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…